Patent · US Active

Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors

US11098062B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Tongfei Wu · Leuven, BE
Dirk Brehmer · Glückstadt, DE
Lijs Beke · Ekeren, BE
An Boeckx · Herentals, BE
Gaston Stanislas Marcella Diels · Turnhout, BE
Edward C. Lawson · Pipersville, US
Lieven Meerpoel · Beerse, BE
Vineet Pande · Vosselaar, BE
Marcus Cornelis Bernardus Catharina Paradé · Eindhoven, NL
Wim Bert Griet Schepens · Sint-Katelijne-Waver, BE
Weimei Sun · North Wales, US
Johannes Wilhelmus John F. Thuring · Ekeren, BE
Marcel Viellevoye · Breda, NL

Key dates

Filing date	Oct 2, 2017
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Oct 2, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.